Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study

This study assessed second-line continued use of cetuximab for treatment of unresectable metastatic colorectal cancer (mCRC) after disease progression during first-line cetuximab-based therapy. Consecutive patients with wild-type KRAS exon 2 and unresectable mCRC were retrospectively enrolled after...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Qingyang, Wei, Ye, Ren, Li, Zheng, Peng, Yu, Yiyi, Ye, Qinghai, Ding, Jianyong, Chen, Jingwen, Chang, Wenju, Zhong, Yunshi, Zhu, Dexiang, Lin, Qi, Yang, Liangliang, Qin, Xinyu, Xu, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905480/
https://www.ncbi.nlm.nih.gov/pubmed/26863631
http://dx.doi.org/10.18632/oncotarget.7193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905480/
https://www.ncbi.nlm.nih.gov/pubmed/26863631
http://dx.doi.org/10.18632/oncotarget.7193

Ejemplares similares